MEC
MCID: MCP006
MIFTS: 48

Mucoepidermoid Carcinoma (MEC) malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Mucoepidermoid Carcinoma

About this section

Aliases & Descriptions for Mucoepidermoid Carcinoma:

Name: Mucoepidermoid Carcinoma 11 48 13 68
Carcinoma, Mucoepidermoid 39
 
Carcinoma Mucoepidermoid 50
Mec 11

Classifications:



External Ids:

Disease Ontology11 DOID:4531
MeSH39 D018277
SNOMED-CT62 4079000
NCIt45 C3772

Summaries for Mucoepidermoid Carcinoma

About this section
NIH Rare Diseases:48 Mucoepidermoid carcinoma is a type of cancer of the salivary glands.  salivary gland cancer is diagnosed in 2-3 individuals per 100,000 people each year, and 30-35% of these are mucoepidermoid carcinomas.   mucoepidermoid carcinoma develops when a cell randomly acquires changes (mutations) in genes that regulate how the cell divides such that it begins to grow quickly, forming a cluster of cells (a mass or lump).  the earliest signs of a mucoepidermoid carcinoma may include a lump in the face, neck, or mouth; numbness, weakness, or pain in part of the face; or difficulty swallowing.  treatment often begins with surgery to remove the entire tumor.  in some cases, radiation therapy and/or chemotherapy may be used after surgery to ensure that no cancer cells remain in the body. last updated: 6/18/2013

MalaCards based summary: Mucoepidermoid Carcinoma, also known as carcinoma, mucoepidermoid, is related to lacrimal gland mucoepidermoid carcinoma and thymus mucoepidermoid carcinoma. An important gene associated with Mucoepidermoid Carcinoma is CRTC1 (CREB Regulated Transcription Coactivator 1), and among its related pathways are CLEC7A (Dectin-1) signaling and O-linked glycosylation. Affiliated tissues include salivary gland, thyroid and lung, and related mouse phenotypes are digestive/alimentary and endocrine/exocrine gland.

Disease Ontology:11 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells.

Wikipedia:71 Mucoepidermoid carcinoma is the most common type of salivary gland malignancy in adults. Mucoepidermoid... more...

Related Diseases for Mucoepidermoid Carcinoma

About this section

Diseases related to Mucoepidermoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 225)
idRelated DiseaseScoreTop Affiliating Genes
1lacrimal gland mucoepidermoid carcinoma33.4CEACAM5, MUC1, MUC5AC
2thymus mucoepidermoid carcinoma33.3MUC1, MUC4, MUC5AC
3laryngeal mucoepidermoid carcinoma33.1CEACAM5, KRT7, MUC1, MUC2, MUC4, MUC5AC
4basaloid squamous cell carcinoma29.7CEACAM5, EGFR, ERBB2, KRT14
5sclerosing mucoepidermoid carcinoma with eosinophilia12.3
6cutaneous mucoepidermoid carcinoma12.1
7lung mucoepidermoid carcinoma12.0
8breast mucoepidermoid carcinoma11.9
9bile duct mucoepidermoid carcinoma11.9
10bronchus mucoepidermoid carcinoma11.8
11trachea mucoepidermoid carcinoma11.8
12paranasal sinus cancer11.1
13mucoepidermoid esophageal carcinoma11.0
14ceruminous carcinoma11.0
15mucoepidermoid thyroid carcinoma10.8
16thyroiditis10.4
17childhood mediastinal neurogenic tumor10.4CRTC1, MAML2
18bronchogenic lung adenocarcinoma10.4CEACAM5, MUC1
19progeria10.3CRTC1, MAML2, MUC1
20radiculopathy10.3KRT7, TP63
21choroid epithelioid cell melanoma10.3MUC2, MUC5AC
22osteosarcoma arising in bone paget's disease10.3CEACAM5, KRT7, MUC5AC
23vulvar angiokeratoma10.3CEACAM5, KRT7, MUC1
24breast adenocarcinoma10.3CEACAM5, KRT7, MUC5AC
25multidrug-resistant tuberculosis10.3CRTC1, MAML2
26tricuspid valve prolapse10.3CRTC1, EGFR, MAML2
27pineal region mature teratoma10.3EGFR, ERBB2
28precursor t-lymphoblastic lymphoma/leukemia10.3CEACAM5, EGFR, MUC1
29anemia of prematurity10.3KRT7, MUC1, MUC2
30maternally-inherited cardiomyopathy and hearing loss10.3MUC2, MUC4, MUC5AC
31pulmonary artery choriocarcinoma10.3CEACAM5, ERBB2
32myopathy, lactic acidosis, and sideroblastic anemia 210.3MUC1, MUC2, MUC5AC
33deep angioma10.3CEACAM5, CRTC1, KRT7, MAML2
34small intestine carcinoid neuroendocrine tumor10.3CEACAM5, MUC1, MUC2
35adenoma10.3
36lateral sinus thrombosis10.3CEACAM5, MUC2, MUC5AC
37aicardi-goutieres syndrome10.3MUC1, MUC2, MUC4
38retina lymphoma10.3MUC1, MUC2, MUC5AC
39postinflammatory pulmonary fibrosis10.3KRT7, MUC1, TP63
40angiolipomatosis, familial10.3ERBB2, KRT7, MUC1
41cervical lymphoepithelioma-like carcinoma10.3EGFR, ERBB2, MUC1
42vulva squamous cell carcinoma10.3CEACAM5, ERBB2, KRT7
43myotonia congenita10.3CEACAM5, ERBB2, KRT7
44skin sarcoma10.3CEACAM5, EGFR, ERBB2
45female breast axillary tail cancer10.3CEACAM5, KRT14, KRT7
46breast granular cell tumor10.3CEACAM5, KRT14, KRT7
47endophthalmitis10.2CALCA, TG
48advanced sleep phase syndrome10.2CEACAM5, KRT7, MUC2
49allergic contact dermatitis10.2EGFR, MUC1, MUC2
50thymoma10.2CEACAM5, KRT7, MUC1, MUC5AC

Graphical network of the top 20 diseases related to Mucoepidermoid Carcinoma:



Diseases related to mucoepidermoid carcinoma

Symptoms & Phenotypes for Mucoepidermoid Carcinoma

About this section

MGI Mouse Phenotypes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.7AREG, EGFR, ERBB2, KRT14, MUC2, MUC5AC
2MP:00053798.1AREG, CHGA, CRTC1, EGFR, ERBB2, KRT14
3MP:00053766.1AREG, CHGA, CRTC1, CRTC3, EGFR, ERBB2

Drugs & Therapeutics for Mucoepidermoid Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Emend16 44 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
FDA Label: Emend
Disease/s that Drug Treats:Chemotherapy-induced Nausea and Vomiting
Indications and Usage:16 EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist,indicated: in combination with other antiemetic agents for the:o prevention of acute and delayed nausea and vomitingassociated with initial and repeat courses of highly emetogeniccancer chemotherapy (HEC) including high-dose cisplatin (1.1)o prevention of nausea and vomiting associated with initial andrepeat courses of moderately emetogenic cancer chemotherapy(MEC) (1.1) for the prevention of postoperative nausea and vomiting (PONV)(1.2)Limitations of Use (1.3) Not studied for the treatment of established nausea and vomiting. Chronic continuous administration is not recommended.
DrugBank Targets:14 1. Substance-P receptor
Mechanism of Action:16 
Target: emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin
Action: inhibitor
FDA: Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targetsof existing therapies for chemotherapy-induced nausea and vomiting (CINV) and postoperative nauseaand vomiting (PONV).Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxicchemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron EmissionTomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupiesbrain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity ofthe 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both theacute and delayed phases of cisplatin-induced emesis.

Drugs for Mucoepidermoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 151)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 3, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
2
CevimelineapprovedPhase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
3
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
4
FluconazoleapprovedPhase 2, Phase 318486386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
5
Megestrol acetateapproved, vet_approvedPhase 368595-33-511683
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
 
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
MGA
Megace
6
Histamineapproved, investigationalPhase 3105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
7
DoxepinapprovedPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Quitaxon
SPBio_000206
SPBio_002325
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
8
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 1, Phase 21967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
9Anti-Infective AgentsPhase 2, Phase 3, Phase 122062
10Cytochrome P-450 Enzyme InhibitorsPhase 2, Phase 33917
11Antimitotic AgentsPhase 3, Phase 1, Phase 25657
12Liver ExtractsPhase 3, Phase 2, Phase 14067
13Steroid Synthesis InhibitorsPhase 2, Phase 31763
14Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 2, Phase 313168
15HormonesPhase 2, Phase 3, Phase 114415
16Contraceptives, OralPhase 31327
17
MegestrolPhase 3683562-63-819090, 3080587
Synonyms:
(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
3562-63-8
AC1L2DG3
C07120
CID19090
Chronopil
Chronopil (TN)
D008535
D08167
DB00351
 
EINECS 222-628-6
HSDB 3233
LS-118488
MGA
Megestrol (INN)
Megestrol Acetate
Megestrol [INN:BAN]
Megestrolo
Megestrolo [DCIT]
Megestrolum [INN-Latin]
Megestryl acetate
UNII-EA6LD1M70M
megestrol
18Adjuvants, AnesthesiaPhase 31674
19Hormone AntagonistsPhase 2, Phase 313180
20Central Nervous System StimulantsPhase 32211
21Appetite StimulantsPhase 365
22Antineoplastic Agents, HormonalPhase 35592
23Contraceptive AgentsPhase 31967
24Anesthetics, IntravenousPhase 32538
25Central Nervous System DepressantsPhase 313403
26Anesthetics, GeneralPhase 32934
27AnestheticsPhase 39596
28AnalgesicsPhase 311733
29Cytochrome P-450 CYP2C9 InhibitorsPhase 2, Phase 3669
30NarcoticsPhase 33646
31Analgesics, OpioidPhase 33238
32Peripheral Nervous System AgentsPhase 323689
33Autonomic AgentsPhase 310150
34Cholinergic AgentsPhase 33992
35Neurotransmitter AgentsPhase 318340
36Antifungal AgentsPhase 2, Phase 3, Phase 13696
37pancreatic polypeptidePhase 3, Phase 120
38Psychotropic DrugsPhase 36430
39
Histamine PhosphatePhase 3104951-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
40Histamine AntagonistsPhase 3961
41Antidepressive Agents, TricyclicPhase 3304
42Antidepressive AgentsPhase 32736
43ColaNutraceuticalPhase 3, Phase 2, Phase 11946
44
IndinavirapprovedPhase 2110150378-17-95362440
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC-20034
AC1L1U7I
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
 
C36H47N5O4
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
indinavir
45
Ritonavirapproved, investigationalPhase 2883155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
46
Paclitaxelapproved, vet_approvedPhase 1, Phase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
47
CisplatinapprovedPhase 1, Phase 2277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
48
Amifostineapproved, investigationalPhase 1, Phase 28120537-88-62141
Synonyms:
Amifostina
Amifostine
Amifostine Ethiofos
Amifostinum
Aminopropylaminoethyl Thiophosphate
 
Apaetp
Ethiofos
Ethyol
Gammaphos
SAPEP
WR-1065
49
LenograstimapprovedPhase 2, Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
50
IfosfamideapprovedPhase 24003778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide (JAN/USP/INN)
 
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,

Interventional clinical trials:

(show top 50)    (show all 80)
idNameStatusNCT IDPhase
1Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
2Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
3Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
4Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
5Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
6Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
7Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
8Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3
9Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck CancerUnknown statusNCT00003251Phase 1, Phase 2
10Antineoplaston Therapy in Treating Patients With Advanced Head and Neck CancerUnknown statusNCT00003489Phase 2
11External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesUnknown statusNCT00637637Phase 2
12Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During SurgeryCompletedNCT00003744Phase 2
13Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2
14Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1, Phase 2
15Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2
16Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland CancerCompletedNCT00002632Phase 2
17High-dose ICE With AmifostineCompletedNCT00003657Phase 2
18Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1, Phase 2
19Docetaxel in Treating Patients With Solid TumorsCompletedNCT00003565Phase 2
20Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck CancerCompletedNCT00448552Phase 2
21Trastuzumab in Treating Patients With Advanced Salivary Gland CancerCompletedNCT00004163Phase 2
22Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth CancerCompletedNCT00004901Phase 1, Phase 2
23Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
24Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1, Phase 2
25Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland TumorCompletedNCT00079079Phase 2
26Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerCompletedNCT00021333Phase 2
27Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck CancerCompletedNCT00509665Phase 2
28Intensity-Modulated or Proton Radiation Therapy for Sinonasal MalignancyRecruitingNCT01586767Phase 2
2918F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyRecruitingNCT01806675Phase 1, Phase 2
30Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By SurgeryRecruitingNCT01220583Phase 2
31Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14RecruitingNCT02857712Phase 2
32Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsActive, not recruitingNCT00859937Phase 2
33Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerTerminatedNCT00126607Phase 2
34Title XELOX FOR SALIVARY GLAND CANCERSTerminatedNCT00101075Phase 2
35MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck CancerUnknown statusNCT00984074Phase 1
36Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
37Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
38Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
397-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
40Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
41Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
42Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerCompletedNCT01637194Phase 1
43Head & Neck Cancer Survivorship: Physical and Functional StatusCompletedNCT00751816Phase 1
44Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
45Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
46Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00010023Phase 1
47Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced CancerCompletedNCT00045006Phase 1
48Vaccine Therapy in Treating Patients With Advanced or Recurrent CancerCompletedNCT00019110Phase 1
49Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT00006036Phase 1
50Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver FunctionCompletedNCT00002901Phase 1

Search NIH Clinical Center for Mucoepidermoid Carcinoma


Cochrane evidence based reviews: carcinoma, mucoepidermoid

Genetic Tests for Mucoepidermoid Carcinoma

About this section

Anatomical Context for Mucoepidermoid Carcinoma

About this section

MalaCards organs/tissues related to Mucoepidermoid Carcinoma:

36
Salivary gland, Thyroid, Lung, Trachea, Breast, Brain, Tongue

Publications for Mucoepidermoid Carcinoma

About this section

Articles related to Mucoepidermoid Carcinoma:

(show top 50)    (show all 661)
idTitleAuthorsYear
1
Bulbar conjunctival metastasis from mucoepidermoid carcinoma of parotid-a case report and review of literature. (28061862)
2017
2
Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-I^/II_BI+/NFI_B axis. (27682876)
2016
3
Comparison of histological grading methods in mucoepidermoid carcinoma of minor salivary glands. (27721274)
2016
4
The use of immunohistochemistry in detection of perineural invasion in mucoepidermoid carcinoma. (27068680)
2016
5
Mucoepidermoid carcinoma of the upper lip. (27712959)
2016
6
Re-evaluation of MAML2 fusion-negative mucoepidermoid carcinoma: a subgroup being actually hyalinizing clear cell carcinoma of the salivary gland with EWSR1 translocation. (27769871)
2016
7
Massive hemoptysis due to primary mucoepidermoid carcinoma of the lung in a 12-year-old. (27216748)
2016
8
Central mucoepidermoid carcinoma radiographically mimicking an odontogenic tumor: A case report and literature review. (27721620)
2016
9
Expression of Amphiregulin in Mucoepidermoid Carcinoma of the Major Salivary Glands: A Molecular and Clinicopathological Study. (27393417)
2016
10
Paediatric mucoepidermoid carcinoma. (26976338)
2016
11
Case of parotid mucoepidermoid carcinoma: Expanding the spectrum of von Hippel-Lindau-related neoplasms. (28006088)
2016
12
Conjunctival Mucoepidermoid Carcinoma. (26902565)
2016
13
The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. (27458536)
2016
14
Recurrent High-Grade Invasive Mucoepidermoid Carcinoma of Larynx: A Case Report and Review of the Literature. (27441076)
2016
15
Mucoepidermoid Carcinoma - Unknown Primary Affecting the Neck. (27272843)
2016
16
Mucoepidermoid Carcinoma of Palatal Minor Salivary Glands with Intracranial Extension: A Case Report and Literature Review. (27781194)
2016
17
Endoscopic Endonasal Resection of Recurrent Nasopharyngeal Mucoepidermoid Carcinoma. (27171943)
2016
18
CRTC1-MAML2 gene fusion in G-CSF-secreting mucoepidermoid carcinoma: an indicator of favourable prognosis? (27101634)
2016
19
Primary mucoepidermoid carcinoma at the carina of trachea presenting with wheezing in an asthmatic child mimicking an attack of asthma: A case report. (27858901)
2016
20
Role of CRTC1/MAML2 Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid Carcinoma. (26796488)
2016
21
Surgery combined with postoperative (125) I seed brachytherapy for the treatment of mucoepidermoid carcinoma of the parotid gland in pediatric patients. (27576792)
2016
22
Sclerosing Mucoepidermoid Carcinoma of the Parotid Gland. (27602340)
2016
23
Mucoepidermoid carcinoma arising in Warthin's tumor of the parotid gland: Clinicopathological characteristics and immunophenotypes. (27417276)
2016
24
Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. (27043340)
2016
25
Pulmonary Mucoepidermoid Carcinoma and Solid Pseudopapillary Neoplasm of the Pancreas: A Coincidence of 2 Rare Tumors in an 8-Year-Old Boy. (27164522)
2016
26
Twist Expression in Pleomorphic Adenoma, Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma of Salivary Glands. (26832177)
2016
27
Oncocytic mucoepidermoid carcinoma: A case report and review of literature. (27773121)
2016
28
MAML2 Status in Mucoepidermoid Carcinoma Can No Longer Be Considered a Prognostic Marker. (27299797)
2016
29
Mucoepidermoid Carcinoma of the Hard Palate in a Young Patient. (27438452)
2016
30
Mucoepidermoid Carcinoma in Carcinosarcoma of the Lung - A Rare Combination. (27136111)
2016
31
Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. (27910944)
2016
32
Mucoepidermoid Carcinoma at the Mandibular Edentulous Ridge Mucosa: An Infrequent Location. (26861234)
2016
33
Mucoepidermoid Carcinoma of the Lingual Tonsil. (27670545)
2016
34
Lacrimal Sac Mucoepidermoid Carcinoma with Metastases to the Cavernous Sinus Following Dacryocystorhinostomy Treated with Stereotactic Radiotherapy. (27462255)
2016
35
Parotid sclerosing mucoepidermoid carcinoma: a case report and immunohistochemical study. (28002531)
2016
36
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. (27340278)
2016
37
Delayed diagnosis of endobronchial mucoepidermoid carcinoma in a 29-year-old male. (27186000)
2016
38
A Rare Case of Exclusively Oncocytic Mucoepidermoid Carcinoma with MAML2 Translocation. (27441073)
2016
39
Extensive Regional Metastasis of High-Grade Mucoepidermoid Carcinoma of an Unknown PrimaryA Tumor. (28042980)
2016
40
Clonal and genetic relationship between individual components of mucoepidermoid carcinoma: X-chromosome inactivation assay and microsatellite analysis. (27327190)
2016
41
Nuclear Multidrug Resistance-Related Protein 1 Is Highly Associated with Better Prognosis of Human Mucoepidermoid Carcinoma through the Suppression of Cell Proliferation, Migration and Invasion. (26829120)
2016
42
Mucoepidermoid carcinoma of the palate: A rare case report. (27143836)
2016
43
Locally Advanced Stage High-Grade Mucoepidermoid Carcinoma of Salivary Gland in a 9-Year-Old Girl: The Controversy of Adjuvant Therapy. (27746885)
2016
44
Dendriform pulmonary ossification in a patient with mucoepidermoid carcinoma. (27252231)
2016
45
SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma. (27327192)
2016
46
Primary Mucoepidermoid Carcinoma of the Lacrimal Sac -a88 a Case Report and Literature Review. (27534787)
2016
47
Diagnostic and prognostic utility of Mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent in situ hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands. (27068311)
2016
48
Embryonic stem cells markers Oct4 and Nanog correlate with perineural invasion in human salivary gland mucoepidermoid carcinoma. (27131799)
2016
49
Secondary mucoepidermoid carcinoma of the orbit. (27146939)
2016
50
Expression of Membrane-Bound Mucins and p63 in Distinguishing Mucoepidermoid Carcinoma from Papillary Cystadenoma. (27278378)
2016

Variations for Mucoepidermoid Carcinoma

About this section

Cosmic variations for Mucoepidermoid Carcinoma:

8 (show all 34)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM483HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinomac.35G>Tp.G12V15
2COSM43680TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.523C>Tp.R175C15
3COSM46283TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.569C>Ap.P190H15
4COSM491HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinomac.39T>Ap.G13G15
5COSM1389051SMAD4salivary gland,NS,carcinoma,mucoepidermoid carcinomac.993G>Ap.M331I15
6COSM44850TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.494A>Tp.Q165L15
7COSM44119TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.483C>Tp.A161A15
8COSM546KRASsalivary gland,NS,carcinoma,mucoepidermoid carcinomac.175G>Ap.A59T15
9COSM46282TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.501G>Cp.Q167H15
10COSM5069PTENsalivary gland,NS,carcinoma,mucoepidermoid carcinomac.760A>Gp.K254E15
11COSM44853TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.661G>Ap.E221K15
12COSM484HRASsalivary gland,NS,carcinoma,mucoepidermoid carcinomac.35G>Ap.G12D15
13COSM43797TP53salivary gland,NS,carcinoma,mucoepidermoid carcinomac.550G>Cp.D184H15
14COSM51381KITsalivary gland,face,carcinoma,NSc.2386A>Gp.R796G12
15COSM1658892HK1salivary gland,mouth floor,carcinoma,NSc.370C>Gp.H124D11
16COSM1658965DYRK4salivary gland,mouth floor,carcinoma,NSc.1733G>Ap.R578H11
17COSM1658935CHEK2salivary gland,mouth floor,carcinoma,NSc.508G>Ap.V170I11
18COSM1659071WASF2salivary gland,mouth floor,carcinoma,NSc.15G>Tp.T5T11
19COSM51382KRASsalivary gland,mouth floor,carcinoma,NSc.50G>Ap.S17N11
20COSM1658899COL22A1salivary gland,mouth floor,carcinoma,NSc.4115G>Cp.G1372A11
21COSM1658780KDM6Asalivary gland,mouth floor,carcinoma,NSc.2833-1G>Ap.?11
22COSM51383BRAFsalivary gland,mouth floor,carcinoma,NSc.1768G>Ap.V590I11
23COSM1658989TP53BP1salivary gland,mouth floor,carcinoma,NSc.3854C>Gp.T1285S11
24COSM1659046THRAsalivary gland,mouth floor,carcinoma,NSc.1162C>Tp.R388W11
25COSM1659047HECTD4salivary gland,mouth floor,carcinoma,NSc.6707G>Ap.S2236N11
26COSM34223AXLsalivary gland,mouth floor,carcinoma,NSc.1522G>Ap.G508S11
27COSM1659036MELKsalivary gland,mouth floor,carcinoma,NSc.817T>Cp.W273R11
28COSM1658912SLC26A2salivary gland,mouth floor,carcinoma,NSc.1474C>Tp.R492W11
29COSM1659003MAP2salivary gland,mouth floor,carcinoma,NSc.31G>Tp.A11S11
30COSM1658880CDAN1salivary gland,mouth floor,carcinoma,NSc.2248G>Tp.G750C11
31COSM1659033RNF38salivary gland,mouth floor,carcinoma,NSc.623A>Gp.H208R11
32COSM1659031TRPV5salivary gland,mouth floor,carcinoma,NSc.554A>Gp.H185R11
33COSM1658983GTF3C3salivary gland,mouth floor,carcinoma,NSc.2602C>Gp.Q868E11
34COSM1658957HNRNPDLsalivary gland,mouth floor,carcinoma,NSc.289C>Tp.R97C11

Expression for genes affiliated with Mucoepidermoid Carcinoma

About this section
Search GEO for disease gene expression data for Mucoepidermoid Carcinoma.

Pathways for genes affiliated with Mucoepidermoid Carcinoma

About this section

GO Terms for genes affiliated with Mucoepidermoid Carcinoma

About this section

Cellular components related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Golgi lumenGO:000579610.2MUC1, MUC2, MUC4, MUC5AC
2nucleusGO:00056345.8AREG, CALCA, CRTC1, CRTC3, EGFR, ERBB2

Biological processes related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1maintenance of gastrointestinal epitheliumGO:003027710.7MUC2, MUC4
2DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.6MUC1, TP63
3negative regulation of ERBB signaling pathwayGO:190118510.5EGFR, ERBB2
4response to lipidGO:003399310.5EGFR, PCNA
5positive regulation of CREB transcription factor activityGO:003279310.3CRTC1, CRTC3
6epithelial cell differentiationGO:003085510.1KRT14, MUC1, PCNA, TP63
7O-glycan processingGO:001626610.0MUC1, MUC2, MUC4, MUC5AC
8protein homotetramerizationGO:00512899.9CRTC1, CRTC3, TP63
9positive regulation of DNA replicationGO:00457409.7AREG, EGFR, PCNA
10stimulatory C-type lectin receptor signaling pathwayGO:00022239.4MUC1, MUC2, MUC4, MUC5AC
11cell proliferationGO:00082839.0AREG, EGFR, ERBB2, MKI67, PCNA

Molecular functions related to Mucoepidermoid Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cAMP response element binding protein bindingGO:000814010.4CRTC1, CRTC3
2signal transducer, downstream of receptor, with protein tyrosine kinase activityGO:00047169.9EGFR, ERBB2
3identical protein bindingGO:00428028.7CALCA, CEACAM5, EGFR, ERBB2, PCNA, TP63

Sources for Mucoepidermoid Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet